Skip to main content

Bimekizumab Side Effects

Medically reviewed by Drugs.com. Last updated on Oct 17, 2023.

Applies to bimekizumab: subcutaneous solution.

Serious side effects of Bimekizumab

Along with its needed effects, bimekizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking bimekizumab:

More common

Less common

Incidence not known

Other side effects of Bimekizumab

Some side effects of bimekizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to bimekizumab: subcutaneous injection.

General

Upper respiratory infections were the most frequently reported adverse reactions, including nasopharyngitis and oral candidiasis.[Ref]

Dermatologic

Tinea Infections included tinea pedis, fungal skin infection, tinea versicolor, tinea cruris, tinea infection, body tinea, and onychomycosis[Ref]

Common (1% to 10%): Acne, folliculitis, rash, tinea infections, dermatitis, eczema, herpes simplex

Uncommon (0.1% to 1%): Dermatitis contact, dyshidrotic eczema, intertrigo[Ref]

Gastrointestinal

Common (1% to 10%): Oral candidiasis, oropharyngeal candidiasis, gastroenteritis, oral herpes

Uncommon (0.1% to 1%): Inflammatory bowel disease, mucosal, and cutaneous candidiasis[Ref]

Oral candidiasis included oropharyngeal candidiasis, oral fungal infection, fungal pharyngitis, and fungal oropharyngitis.

Gastroenteritis included enterovirus infection, gastroenteritis bacterial, and gastroenteritis viral.[Ref]

Hematologic

Uncommon (0.1% to 1%): Neutropenia[Ref]

Hepatic

Common (1% to 10%): Elevated liver enzymes[Ref]

Hypersensitivity

Frequency not reported: Hypersensitivity reactions including anaphylactic reactions[Ref]

Immunologic

Very common (10% or more): Anti-drug antibodies (up to 45%)[Ref]

Local

Injection site reactions included injection site erythema, injection site edema, injection site pain, injection site bruising, and injection site swelling.[Ref]

Common (1% to 10%): Injection site reactions[Ref]

Nervous system

Common (1% to 10%): Headache[Ref]

Ocular

Uncommon (0.1% to 1%): Conjunctivitis[Ref]

Other

Other candida infections included vulvovaginal candidiasis, vulvovaginal mycotic infection, skin candida, and genital candidiasis.[Ref]

Common (1% to 10%): Fatigue

Uncommon (0.1% to 1%): Otitis externa, otitis media, other candida infections[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infection (up to 15%)[Ref]

Upper respiratory tract infections included nasopharyngitis, pharyngitis, rhinitis, viral upper respiratory tract infection, sinusitis, tonsillitis, pharyngitis streptococcal, pharyngitis bacterial, viral rhinitis, influenza, and peritonsillar abscess.[Ref]

Psychiatric

Common (1% to 10%): Passive suicidal ideation, completed suicide, attempted suicide[Ref]

References

1. Product Information. Bimzelx (bimekizumab). UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia. 2023.

2. Product Information. Bimzelx (bimekizumab). UCB Pharma Ltd. 2023.

3. Product Information. Bimzelx Prefilled Syringe (bimekizumab). UCB Pharma Inc. 2023.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.